Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

McGill University

$24,567.00

Novel synthetic strategies for the preparation of tricyclic molecular scaffolds towards anti-cancer drug candidates

FY 2013-14

Summary
The pharmaceutical R&D group at Epigenetix identified a series of high affinity, drug-like inhibitors of a keypharmacological target for the treatment of cancer. Unfortunately, their efforts to further develop these asclinical therapeutics has been impeded by the complexity of their syntheses. In this proposal, Epigenetix andthe Moitessier research groups will join forces to identify improved synthetic approaches to allow Epigenetix toadvance this chemical series and to explore and optimize the compounds in preclinical in vivo models, assessany liabilities and drive further optimization. Epigenetix aims to progress these compounds into Phase-1clinical development for the treatment of cancer.Moitessier's research interests are in line with Epigenetix's interests and his expertise will be fundamental tosolve the synthetic issue that Epigenetix faces.
Program
Engage Grants Program
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
447277-2013
Name nom
Moitessier, Nicolas
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
24567
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
1
Nb partie
1
Application title
Novel synthetic strategies for the preparation of tricyclic molecular scaffolds towards anti-cancer drug candidates
Keyword
NSERC
Application summary
The pharmaceutical R&D group at Epigenetix identified a series of high affinity, drug-like inhibitors of a keypharmacological target for the treatment of cancer. Unfortunately, their efforts to further develop these asclinical therapeutics has been impeded by the complexity of their syntheses. In this proposal, Epigenetix andthe Moitessier research groups will join forces to identify improved synthetic approaches to allow Epigenetix toadvance this chemical series and to explore and optimize the compounds in preclinical in vivo models, assessany liabilities and drive further optimization. Epigenetix aims to progress these compounds into Phase-1clinical development for the treatment of cancer.Moitessier's research interests are in line with Epigenetix's interests and his expertise will be fundamental tosolve the synthetic issue that Epigenetix faces.